KR101406138B1 - Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille - Google Patents
Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille Download PDFInfo
- Publication number
- KR101406138B1 KR101406138B1 KR1020110014116A KR20110014116A KR101406138B1 KR 101406138 B1 KR101406138 B1 KR 101406138B1 KR 1020110014116 A KR1020110014116 A KR 1020110014116A KR 20110014116 A KR20110014116 A KR 20110014116A KR 101406138 B1 KR101406138 B1 KR 101406138B1
- Authority
- KR
- South Korea
- Prior art keywords
- diabetes
- dendropanoxide
- composition
- group
- present
- Prior art date
Links
- KSXPPAGQQYHJFU-UHFFFAOYSA-N Dendropanoxid Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2C1(O1)CCC1C2(C)C KSXPPAGQQYHJFU-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 63
- 239000000203 mixture Substances 0.000 title abstract description 31
- 241000392544 Dendropanax morbifer Species 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 16
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract description 16
- 102000004877 Insulin Human genes 0.000 abstract description 15
- 108090001061 Insulin Proteins 0.000 abstract description 15
- 239000008103 glucose Substances 0.000 abstract description 15
- 229940125396 insulin Drugs 0.000 abstract description 15
- 229960003624 creatine Drugs 0.000 abstract description 8
- 239000006046 creatine Substances 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 5
- 230000003907 kidney function Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 206010019851 Hepatotoxicity Diseases 0.000 abstract description 3
- 231100000304 hepatotoxicity Toxicity 0.000 abstract description 3
- 230000007686 hepatotoxicity Effects 0.000 abstract description 3
- 201000001421 hyperglycemia Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 229960001031 glucose Drugs 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 8
- 229960001052 streptozocin Drugs 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229940045136 urea Drugs 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241000238814 Orthoptera Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- JVGFZGDTAYCUDA-UHFFFAOYSA-N Di-Me ester-(5S,11bR)-form-2,3,6,11-Tetrahydro-3-oxo-1H-indolizino[8,7-b]indole-5,11b(5H)-dicarboxylic acid Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(O3)C1CCC3C2(C)C JVGFZGDTAYCUDA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000000569 Musa basjoo Species 0.000 description 1
- 235000000139 Musa basjoo Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000009956 embroidering Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Abstract
황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물은 간독성이 없으면서도 혈중의 포도당 및 인슐린의 수치를 낮추어 과혈당 증상을 완화시키고, 요소, 요산, 크레아틴등의 농도를 낮추어 신장기능저하를 억제하여 당뇨병의 효과적인 예방 및 치료 효능이 있다. 따라서 상기 조성물을 이용하여 당뇨병의 예방 및 치료를 위한 의약품 및 당뇨병의 예방 및 개선을 위한 건강기능식품에 사용할 수 있다. A pharmaceutical composition for the prevention or treatment of diabetes comprising dendropanoxide (DP) as an active ingredient isolated from Hwangcholgak tree lowers blood glucose and insulin levels without hepatotoxicity and alleviates hyperglycemia symptoms, , Creatine, and the like to lower the kidney function, thereby effectively preventing and treating diabetes. Therefore, the composition can be used in medicine for prevention and treatment of diabetes and health functional food for prevention and improvement of diabetes.
Description
본 발명은 황칠나무로부터 분리한 덴드로파녹사이드(Dendropanoxide)를 유효성분으로 포함하는 당뇨병 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of diabetes comprising dendropanoxide (Dendropanoxide) isolated from U. grubu as an active ingredient.
당뇨병은 대표적인 만성 성인병의 하나로, 우리나라의 당뇨병 환자는 전체 인구의 약 5% 정도로 최소한 250만 명으로 추정되고 있다. 선진국의 경우에 당뇨병 환자 수가 매년 급증하고 있으며, 우리나라도 생활수준의 향상과 더불어 생활양식이 서구화되면서 점차로 환자의 수가 증가되고 있다. Diabetes mellitus is one of the most common chronic diseases, and about 5% of the total population of the country is estimated to have at least 2.5 million people. In advanced countries, the number of diabetic patients is increasing rapidly. In Korea, the number of patients is gradually increasing as the living standard is improved and the lifestyle is westernized.
당뇨병은 발생하는 기전에 따라 크게 두 가지로 나눌 수 있다. 첫 번째, 인슐린 의존형 당뇨병 (Type I. Insulin dependent diabetes mellitus, IDDM)은 당뇨병 환자의 약 10%를 차지하며, 대개 20세 이하의 어린 연령층에 발병하므로 유전성인 것으로 보이며, 일명 소아당뇨병 (juvenile onset diavetes)이라고 한다. 이는 특정한 human lymphocyte antigen (HLA)과 바이러스 감염 등으로 췌장의 랑겔한스섬의 베타세포가 파괴되어 인슐린의 분비가 되지 않아 발병하는 당뇨병으로, 일반적으로 체중이 감소하고 케톤증 (Ketonacidosis)이 되기 쉽다. 인슐린 투여로 치료가 가능하고 급성 형태가 많으며, 여아에게 발생빈도가 높고 성인보다 어린이에게 주로 나타난다. 두 번째, 인슐린 비의존형 당뇨병 (Type II. Noninsulin dependent diabetes mellitus NIDDM)은 40세 이후에 발병하는 성인형 당뇨병 (adult onset diabetes)이라고도 하며, 운동부족과 비만, 과식, 스트레스 등으로 인하여 근육이나 지방조직 등 말초조직에서 인슐린에 대한 감수성이 둔화되어 당대사의 장애가 4~5년 이상 오랜 기간 지속되어 발병하게 된다. 제 2형 당뇨병은 식사요법과 운동요법으로 체중을 줄이면 50~80%는 치유가 되며, 인슐린을 투여하지 않아도 생명에는 지장이 없을 정도이므로 인슐린 비의존형 당뇨병이라고 한다. 이 외에 영양실조 관련 당뇨병 (제 3형 당뇨병)이 있으며, 이것은 제 3세계, 특히 열대지방에서 나타나는 젊은이 당뇨병으로 유아기에 영양실조의 병력을 가진 경우에 나타나는 당뇨병으로, 앞서 두 형태의 당뇨병과 약간 다른 모습을 보여, 세계보건기구는 이를 독립된 형으로 분리하였다. Diabetes mellitus can be classified into two types depending on the mechanism of the occurrence. First, insulin-dependent diabetes mellitus (IDDM) accounts for about 10% of diabetic patients, and it appears to be hereditary because it usually occurs in children younger than 20 years of age, aka juvenile onset diabetic ). It is a diabetic disease that is caused by a specific human lymphocyte antigen (HLA) and viral infection, which causes the beta cells of the pancreas to destroy the insulin secretion, and is generally prone to lose weight and become ketonacidosis. It is possible to treat with insulin administration, has many acute forms, has a high incidence in girls, and appears mainly in children. The second type, noninsulin dependent diabetes mellitus (NIDDM), is also known as adult onset diabetes, which occurs after the age of 40, and is characterized by a lack of exercise, obesity, overeating, , The susceptibility to insulin in the peripheral tissues is slowed, and the disability of the patient usually lasts for 4 to 5 years or longer. Type 2 diabetes mellitus diet and exercise therapy to lose weight by 50 to 80% of the healing, and without the insulin dose is not enough to hinder the life of non-insulin-dependent diabetes mellitus is called. In addition, there is a malnutrition-related diabetes (type 3 diabetes), which is a young diabetes mellitus in the third world, especially in the tropics. It is a diabetes mellitus with a history of malnutrition in infancy. The World Health Organization has separated it into its independent form.
당뇨병 치료의 가장 중요한 목표는 혈당치를 가능한 정상 수치에 가깝게 조절하는 것인데, 공복혈당과 함께 식ㆍ후 혈당 조절이 당뇨병 증세의 개선과 합병증의 예방 및 치료에 있어서 중요하며, 치료방법으로 약물요법, 식이요법 및 운동 요법이 있다 (Ref. Jenkins, D.J.A., Woever et.al., starchy food and glycemic index,Diabetes care, 11, pp149-159, 1988).The most important goal of diabetes treatment is to adjust the blood glucose level as close to the normal level as possible. In addition to fasting blood glucose, dietary and postprandial blood glucose control is important in the improvement of diabetic symptoms and prevention and treatment of complications. (Ref. Jenkins, DJA, Woever et al., Starchy food and glycemic index, Diabetes care, 11, pp. 149-159, 1988).
그러나 흔히 사용되는 약물요법은 인슐린 및 화학적 경구혈당강하제 등의 화학물질을 사용하고 있어 약물복용에 따른 부작용과 환자의 내성이 끊임없는 문제가 되고 있어 이 때문에 천연물을 이용한 당뇨병 치료제의 개발은 매우 중요한 의미를 가진다.However, since commonly used drug therapies use chemicals such as insulin and chemical hypoglycemic agents, adverse effects due to drug administration and patient tolerance are a constant problem. Therefore, development of a therapeutic agent for diabetes using natural products is very important .
한편, 황칠나무 (Dendropanax morbifera Lev.)는 우리나라 남해안의 일부 도서지역에만 자생하는 두릅나무과에 속하는 상록교목으로, 수피에 상처를 내면 황색의 액이 나오는데 이것을 황칠(黃漆)이라 하며 오래전부터 가구 등에 칠로서 사용되어왔다 (이창복, 대한식물도감, 향문사, 1982).On the other hand, Dendropanax morbifera Lev. Is an evergreen tree belonging to Araliaceae which grows only in a part of the southern coast of Korea. When it bruises on the bark, yellow liquid comes out. It is called 黄 漆, (Lee Chang-bok, Korean Botanical Illustrated Book, 1982).
황칠은 아름다운 황금빛이 나는 천연 투명 도료로서, 옛 백제의 특산품이었으며 조선시대에도 부채나 화선지 등에 칠로서 사용되었고 특히 황칠을 한 목공예품은 높이 평가되었다. 황칠은 금빛을 띠면서도 바탕의 나무결을 생생하게 떠오르게 하여 목공예품을 한층 화사하게 치장하는 최상의 도료일 뿐만 아니라 락카나 옻칠과는 달리 항파단성이 있어 부채에도 칠할 수 있는 장점이 있다. 이러한 황칠의 우수성 때문에 황칠을 한 것만이 우리의 전통공예품이라고 주장하는 부류의 사람도 있다.Hwangchil is a beautiful golden painted transparent paint. It was a special product of old Baekje. It was used as a paint for fan and flowerpot in Chosun Dynasty. Huangchil is not only the best paint for embroidering woodwork, but it also has the advantage of being able to paint on the fan because it has anti-irregularity, unlike lacquer or lacquer. There are some people who argue that the only thing that makes yellow crickets is our traditional handicrafts is because of the excellence of these yellow crickets.
황칠나무는 중국 당태종이 백제에 사신을 보내어 구할 정도로 귀하게 사용되었고, 명나라 이시진이 저술한 본초강목 (本草綱目)에는 황칠나무가 번열 (몸에 열이 몹시 나고 가슴속이 답답하며 괴로운 증세) 제거, 술해독, 안질 및 황달 치료, 화상 치료, 나병 치료 등에 효과가 있음이 기술되어 있다 (이시진, 본초강목, 중국 문광도서, 1590).Hwangchil was used to the extent that the Chinese Taejong were sent to the Baekje to save its envoys, and the Mongolian Ishijin wrote the Hwanggakseok, which is a burnt tree, It has been described that it is effective in alcohol detoxification, eye and jaundice treatment, burn treatment, leprosy treatment (Ishin Jin, Basho Gangmok, Munkwang Book, 1590).
최근 황칠나무와 관련된 연구결과에 따르면 황칠이 항암, 항산화 효과, 간세포 재생, 경조직 세포 재생 등에 효과적인 것으로 밝혀졌으나, 당뇨병과 관련된 연구는 현재까지 알려진 바가 없다.Recently, it has been found that Huangchil is effective against anticancer, antioxidant effect, hepatocyte regeneration, and hard tissue cell regeneration, but studies related to diabetes have not been known until now.
이에, 본 발명자들은 오랫동안 다양한 병증에 대하여 치료효능을 보인 황칠나무를 이용하여 당뇨병 치료제를 찾기 위한 연구를 계속 하던 중, 황칠나무의 잎에서 분리한 리그난 계열의 덴드로파녹사이드 (Dendropanoxide, DP)가 당뇨모델 동물실험에서 간독성이 없으면서도 혈중 포도당 및 인슐린 수치를 낮추고, 요소, 요산, 크레아틴의 수치를 낮추는 등 당뇨병에 대해 치료 효능을 보이는 것을 확인함으로써 본 발명을 완성하였다. Accordingly, the inventors of the present invention have been studying for a long time to find a therapeutic agent for diabetes by using Hwangchil, which has been shown to have a therapeutic effect for various diseases. Dendropanic acid (DP) The present inventors completed the present invention by confirming that the model animal test showed a therapeutic efficacy against diabetes, such as lowering of blood glucose and insulin levels and lowering of urea, uric acid and creatine, even without hepatotoxicity.
본 발명의 목적은 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물을 제공하는데 있다. It is an object of the present invention to provide a pharmaceutical composition for preventing or treating diabetes, which comprises dendropanoxide (DP) isolated from Hwangchunjang as an active ingredient.
또한 본 발명의 다른 목적은 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 개선용 식품 조성물을 제공하는데 있다. Another object of the present invention is to provide a food composition for preventing or ameliorating diabetes, which comprises dendropanoxide (DP) isolated from Hwangchunjang as an active ingredient.
상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물을 제공한다.In order to accomplish the object of the present invention, the present invention provides a pharmaceutical composition for preventing or treating diabetes, comprising dendropanoxide (DP) isolated from U. grubu as an active ingredient.
또한 본 발명은 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 개선용 식품 조성물을 제공한다.
The present invention also provides a food composition for preventing or ameliorating diabetes, comprising dendropanoxide (DP) isolated from U. grubu as an active ingredient.
이하 본 발명에 대하여 보다 상세히 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명의 덴드로파녹사이드 (Dendropanoxide, DP)는 하기와 같이 수득될 수 있다. The dendropanoxide (DP) of the present invention can be obtained as follows.
황칠나무의 잎을 물로 세척하여 이물질을 제거한 후 그늘에서 건조하고 분쇄한다. 황칠나무의 잎은 재배한 것 또는 시판되는 것 등 제한 없이 사용할 수 있다. 분쇄된 황칠나무의 잎에 적당한 양의 용매를 첨가하여 완전히 침지되도록 한다. 추출 용매로는 물, 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합 용매로부터 선택된 용매가 바람직하며, 보다 바람직하게는 메탄올이다. 추출방법은 실온에서 함침하거나 가온할 수 있으며, 보다 바람직하게는 30 ℃에서 4시간 동안 환류 추출한다. 다음 상기에서 얻은 황칠나무의 잎 메탄올 추출물을 여과, 농축 후 물 및 메탄올의 혼합용매를 이동상으로 이용한 컬럼 크로마토그래피, 바람직하게는 C18, 세파덱스 LH-20 및 XAD 수지로 이루어진 그룹으로부터 선택된 충진제를 이용한 컬럼 크로마토그래피를 수행하여 분획물을 얻는다. 컬럼 크로마토그래피는 필요에 따라 적절한 충진제를 선택하여 수차례 실시할 수 있다. 이 후 TLC 또는 HPLC 등 크로마토그래피를 통해 활성 화합물을 수득한다. Wash the leaves of Hwangchilmyeo with water to remove foreign matter, then dry and crush in the shade. Leaves of Uchihaku can be used without restrictions such as those cultivated or marketed. A suitable amount of solvent is added to the leaves of the crushed woody trees so that they are completely immersed. As the extraction solvent, a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof is preferable, and methanol is more preferable. The extraction method can be impregnated or warmed at room temperature, more preferably at reflux for 4 hours at 30 占 폚. Next, the methanol extract of Leafwood of Leucaceae was filtered, concentrated and subjected to column chromatography using a mixed solvent of water and methanol as a mobile phase, preferably using a filler selected from the group consisting of C18, Sephadex LH-20 and XAD resin Column chromatography is performed to obtain fractions. The column chromatography can be carried out several times by selecting an appropriate filler as necessary. The active compound is then obtained via chromatography, such as TLC or HPLC.
본 발명은 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention or treatment of diabetes, comprising dendropanoxide (DP) isolated from Hwangcholgak tree as an active ingredient.
본 발명에서 '당뇨병'이란 당대사 기능 이상을 특징으로 하는 만성질환이다. 상기 당뇨병은 혈중 포도당 농도를 조절하는 가장 중요한 호르몬인 인슐린의 절대적 생산 결핍의 결과 (인슐린 의존형 당뇨병 또는 제1형 당뇨병)이거나 표적 장기에서의 인슐린의 작용저하의 결과로 인해 유발된다 (인슐린 비의존형 당뇨병 또는 제2형 당뇨병).In the present invention, 'diabetes' is a chronic disease characterized by abnormal glucose metabolism. The diabetes is the result of an absolute production deficiency of insulin (insulin-dependent diabetes mellitus or type 1 diabetes), which is the most important hormone that regulates blood glucose concentration, or as a result of insulin action in target organs (non-insulin dependent diabetes mellitus Or type 2 diabetes).
본 발명의 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다. The pharmaceutical composition for preventing or treating diabetes, which comprises dendropanoxide (DP) as an active ingredient, which is isolated from Hwangchu-myeon of the present invention, further comprises suitable carriers, excipients and diluents conventionally used for the production of pharmaceutical compositions can do.
본 발명에 따른 약학적 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌 (Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 덴드로파녹사이드 (Dendropanoxide, DP)와 함께 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스 (sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The pharmaceutical composition according to the present invention may be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like oral preparation, external preparation, suppository and sterilized injection solution according to a conventional method . Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, , Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate (calcium), dendropanic acid carbonate, sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학적 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 바람직한 효과를 위해서 본 발명의 약학적 조성물은 1일 0.0001 내지 100 ㎎/㎏으로, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다.The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For the desired effect, the pharmaceutical composition of the present invention is preferably administered at a daily dose of 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg.
투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량 및 투여횟수는 본 발명의 범위를 한정하는 것은 아니다.The administration may be carried out once a day or divided into several times. The dose and the number of administrations do not limit the scope of the present invention.
본 발명의 약학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
또한, 본 발명의 약학적 조성물은 당뇨병의 예방 또는 치료하는 효과를 가지는 공지의 화합물과 병행하여 투여할 수 있다.In addition, the pharmaceutical composition of the present invention may be administered in combination with a known compound having an effect of preventing or treating diabetes.
본 발명은 황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 개선용 건강기능식품을 제공한다.The present invention provides a health functional food for preventing or ameliorating diabetes, which comprises dendropanoxide (DP) isolated from U. grubu as an active ingredient.
본 발명의 조성물은 식품으로 복용할 수 있는 어떠한 제형으로도 적용하여 사용할 수 있으며 그 예로 분말, 과립제, 정제, 환제, 캅셀제, 연질캅셀제 또는 액제 등을 포함한다. 이러한 본 발명의 조성물을 첨가할 수 있는 식품으로는, 육류, 차 등의 음료수, 스넥류, 과자류, 라면류, 기타 면류, 캔디, 초콜릿, 아이스크림류, 껌, 비타민 복합제, 건강 기능 식품류 등이 있다.The composition of the present invention can be applied to any form that can be taken as food, and examples thereof include powders, granules, tablets, pills, capsules, soft capsules, liquids and the like. Foods to which the composition of the present invention can be added include beverages such as meat and tea, snacks, confectionery, ramie noodles, noodles, candy, chocolate, ice cream, gum, vitamin complex, and health functional foods.
본 발명의 조성물을 포함하는 건강 음료는 지시된 비율로 필수 성분으로서 상기 물질을 포함하는 것 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 (타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Health drinks containing the composition of the present invention are not particularly limited to liquid ingredients except that they contain the above ingredients as essential ingredients in the indicated ratios and include various flavors or natural carbohydrates such as ordinary beverages as additional ingredients . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.
In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. These components may be used independently or in combination.
황칠나무로부터 분리한 덴드로파녹사이드 (Dendropanoxide, DP)를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물은 간독성이 없으면서도 혈중의 포도당 및 인슐린의 수치를 낮추어 과혈당 증상을 완화시키고, 요소, 요산, 크레아틴등의 농도를 낮추어 신장기능저하를 억제하여 당뇨병의 효과적인 예방 및 치료 효능이 있다. 따라서 상기 조성물을 이용하여 당뇨병의 예방 및 치료를 위한 의약품 및 당뇨병의 예방 및 개선을 위한 건강기능식품에 사용할 수 있다.
A pharmaceutical composition for the prevention or treatment of diabetes comprising dendropanoxide (DP) as an active ingredient isolated from Hwangcholgak tree lowers blood glucose and insulin levels without hepatotoxicity and alleviates hyperglycemia symptoms, , Creatine, and the like to lower the kidney function, thereby effectively preventing and treating diabetes. Therefore, the composition can be used in medicine for prevention and treatment of diabetes and health functional food for prevention and improvement of diabetes.
도 1은 황칠나무로부터 분리한 Dendropanoxide의 분자구조이다.
도 2는 실험예 2에서 측정한 실험기간 동안 랫트의 체중 변화 데이터이다.
도 3은 실험예 3에서 DP 의 당뇨 치료 효과를 확인하기 위한 혈중 포도당, 인슐린, 중성지방, 총 콜레스테롤 량 측정 데이터이다.
도 4는 실험예 4에서 측정한 DP 의 신장 기능 개선에 미치는 영향을 확인하기 위한 혈중 요소, 요산, 크레아틴 량 측정 데이터이다.
도 5는 실험예 5에서 측정한 DP 의 간 독성을 확인하기 위한 혈중 AST, ALT를 측정한 데이터이다. FIG. 1 shows the molecular structure of dendropanoxid separated from Hwangchu.
Fig. 2 is data on the body weight change of the rats during the experimental period measured in Experimental Example 2. Fig.
FIG. 3 is a graph showing blood glucose, insulin, triglyceride and total cholesterol level data for confirming the diabetic therapeutic effect of DP in Experimental Example 3. FIG.
4 is data of blood component, uric acid, and creatine amount for confirming the effect of DP on the improvement of renal function measured in Experimental Example 4. FIG.
FIG. 5 is a graph showing blood serum AST and ALT measurements for confirming hepatic toxicity of DP measured in Experimental Example 5. FIG.
이하 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예를 제시한다. 그러나 하기의 실시예 및 실험예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 실시예 및 실험예에 의해 본 발명의 내용이 한정되는 것은 아니다.
Hereinafter, preferred embodiments and experimental examples are provided to facilitate understanding of the present invention. However, the following examples and experimental examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples and experimental examples.
실시예Example 1 : One : DendropanoxideDendropanoxide (( DPDP )의 제조)
대한민국 전라북도 전주시에 위치한 Korea Horticulture sapling Co.에서 구입한 황칠나무의 잎을 건조시킨 후, 10 kg의 잎을 30 ℃에서 메탄올에 4시간 동안 환류 추출하였다(0.5L씩 3회). 수득된 메탄올 추출물을 와트만 No.1 필터를 이용하여 흡입 여과 후 소수성 레진인 Amberlite XAD-16(sigma Co, St.Louis, MO, USA)를 이용하여 농축하고, 다시 메탄올에 녹여 메탄올 층을 분리하였다. 이후 10 % 메탄올에서 100 % 메탄올까지 농도구매를 달리한 컬럼에 C18 미디어 (Merck Co. Gibbstown, NJ, USA)를 이용해 분리하고, 분리층을 다시 Sephadex LH-20 (Amersham, England)를 이용하여 이동상 컬럼 크로마토그래피 (메탄올, 5 mL/min)를 통해 분리하였다. 얻어진 추출물은 CHCl3:MeOH 25%인 용매를 이용한 실리카 겔 TLC (Thin layer chromatography)에서 보이는 유사성을 통해 총 네 개의 주요 부분 (DML 3-7, DML 9-11, DML 14-17, DML 20-28)으로 나뉘어 진 후 이 중 DML 14-17 추출물을 상온에서 밤새 아세톤에 녹여 Dendropanoxide (DP)를 얻어내었다. 최종적으로 semipreparative HPLC [Gilson trilution system; YMC-Pack Pro C18 (S-5 μm, 250 × 20mm i.d. YMC Europe GMBH) column; ACN?H2O (3:7, v/v); UV detection, 254 nm]를 수행해 정제하였고, 분리된 물질의 순수도는 96.0~99.5 %로 확인되었다.
After drying the leaves of Hwangchujang, purchased from Korea Horticulture Sapling Co. located in Jeonju City, Jeollabuk-do, Jeollabuk-do, 10 kg leaves were extracted with methanol at 30 ℃ for 4 hours (3 times 0.5L each). The obtained methanol extract was filtered by suction using a Wattmann No. 1 filter and concentrated using a hydrophobic resin Amberlite XAD-16 (Sigma Co, St. Louis, Mo., USA). The methanol extract was dissolved again in methanol to separate a methanol layer Respectively. Then, the column was separated by using C18 media (Merck Co., Gibbstown, NJ, USA) in a column in which the concentration was changed from 10% methanol to 100% methanol, and the separation layer was separated again using Sephadex LH-20 (Amersham, England) The residue was separated by column chromatography (methanol, 5 mL / min). The extracts obtained showed a total of four major parts (DML 3-7, DML 9-11, DML 14-17, DML 20-28) through a similarity in the silica gel TLC (thin layer chromatography) using a solvent of CHCl3: ), And DML 14-17 extract was dissolved in acetone at room temperature overnight to obtain Dendropanoxide (DP). Finally, semipreparative HPLC [Gilson trilution system; YMC-Pack Pro C 18 (S-5 μm, 250 × 20 mm id YMC Europe GMBH) column; ACN H 2 O (3: 7, v / v); UV detection, 254 nm], and the pureness of the separated material was found to be 96.0 to 99.5%.
실험예Experimental Example 1. One. DP 의Of DP 당뇨병에 대한 치료효과를 확인하기 위한 동물실험 설계 Animal Experimental Design to Identify the Therapeutic Effect on Diabetes
실험예Experimental Example 1-1. 실험동물의 유지 1-1. Maintenance of experimental animals
실험동물은 SLC사 (Shizuoka Prefecture, Japan)에서 구입한 200~250 g 사이 무게를 가지는 수컷 Wistat rat를 사용하였다. SPF (Specific pathogen-free)시설에서 유지하였으며 물과 사료는 자유롭게 먹을 수 있게 하였다. 온도 20-22 ℃, 습도 55-59 %를 유지하고, 12시간 간격으로 명암주기를 유지하였다. Male Wistat rats weighing between 200 and 250 g were purchased from SLC (Shizuoka Prefecture, Japan). SPF (Specific pathogen-free) facility, and water and feed were freely available. The temperature was maintained at 20-22 ° C and the humidity was maintained at 55-59%, and the light and dark cycles were maintained at intervals of 12 hours.
실험예Experimental Example 1-2. 당뇨병 유발 1-2. Inducing diabetes
임의로 한 그룹당 6마리씩으로 나누어 실험에 이용하였다. 총 9개의 그룹으로 나누었으며 Ⅰ 군에서 Ⅳ 군까지는 당뇨병를 유발시키지 않은 정상 랫트가 음성 대조군으로 사용되었다. Ⅴ 군에서 Ⅸ 군까지는 STZ (Streptozotocin)에 의해 당뇨병을 유발시켰다. 당뇨병 유발군의 경우 STZ 70 mg/kg 를 복강 주사하고, 5일 뒤 혈당을 측정하여 공복 혈당지수가 180 mg/dL 이상으로 당뇨병이 유발된 것을 확인 하였다. 총 14일의 실험 기간 동안 Ⅰ, Ⅴ 군은 운반체인 아카시아 검만을, Ⅱ, Ⅵ 군은 실험예 1에서 제조한 DP 30 mg/kg를, Ⅲ, Ⅶ 군은 DP 60 mg/kg를 Ⅳ, Ⅷ 군은 DP 100 mg/kg를 복강 주사하였다. 양성대조군으로 Ⅸ 군은 공지된 당뇨병 치료제인 글리벤클라마이드 (Glibenclamide) 60 μg/kg를 복강 주사하여 DP의 당뇨병 치료 효능을 비교 검증하였다.
Six animals were randomly assigned to each group. The rats were divided into 9 groups, and normal rats without diabetes mellitus from group Ⅰ to group Ⅳ were used as negative controls. From group V to group IX, diabetes was induced by STZ (Streptozotocin). In the diabetic group, STZ 70 mg / kg was intraperitoneally injected. After 5 days, blood glucose was measured and it was confirmed that the diabetic group was induced with a fasting blood glucose level of 180 mg / dL or more. During the 14 days of experiment, acacia suture alone was used as a carrier in the groups I and V,
실험예Experimental Example 2. 체중변화 측정 2. Weight change measurement
실험 첫날과 14일이 경과한 후의 랫트의 무게를 측정하여 실험기간 동안 체중 변화를 분석하였다. The weight of the rats after the first and 14 days of the experiment was measured and the weight change was analyzed during the experiment.
도 2에 나타낸 바와 같이 당뇨병이 유발되지 않은 정상 랫트에서는 체중 증가가 있었던 반면, STZ에 의해 당뇨병이 유발된 랫트에서는 체중 감소가 확인되었다. 이는 당뇨병의 대표적인 병증 중의 하나로 당 대사의 이상과 조직 단백질의 파괴로 인하여 나타나는 현상이다. 반면 DP를 투여한 실험군 (Ⅴ ~Ⅷ)에서는 대조군에 비해 현저한 체중 감소가 보이지 않아 당뇨병 치료 효능을 확인할 수 있었다.
As shown in FIG. 2, weight gain was observed in normal rats not induced by diabetes, whereas weight loss was observed in diabetics induced by STZ. This is one of the typical diseases of diabetes, which is caused by abnormal glucose metabolism and destruction of tissue proteins. On the other hand, no significant weight loss was observed in DP - treated group (Ⅴ ~ Ⅷ) compared to the control group.
실험예Experimental Example 3. 혈중 포도당, 인슐린, 중성지방, 총 콜레스테롤 측정 3. Measure blood glucose, insulin, triglyceride, total cholesterol
실험예 1의 랫트를 실험 마지막 날 12 시간 동안 공복상태를 유지하고 심장으로부터 혈액 샘플을 채취하였다. 이 후 원심분리를 통해 혈청만을 분리하여 냉동보관 후 분석에 이용하였다. The rats of Experimental Example 1 were kept fasted for 12 hours on the last day of the experiment and a blood sample was taken from the heart. After that, serum was separated by centrifugation and used for analysis after freezing storage.
STZ에 의한 당뇨병은 췌장의 베타세포가 파괴되어 인슐린이 제대로 분비되지 못해 높은 혈당이 유지되기 때문에 발병된다. 또한 당뇨병이 발병되었을 경우 혈중의 지질성분이 높아짐이 보고되어, 상기 네 가지 물질 (포도당, 인슐린, 중성지방, 총 콜레스테롤)의 농도는 당뇨병의 치료 효과를 확인하는 지표로 사용된다.Diabetes caused by STZ is caused by the fact that the beta cells of the pancreas are destroyed and insulin is not properly secreted and high blood sugar is maintained. Also, it has been reported that the lipid component of the blood increases when the diabetes develops, and the concentration of the above four substances (glucose, insulin, triglyceride, total cholesterol) is used as an index for confirming the therapeutic effect of diabetes.
도 3에 나타낸 바와 같이 당뇨병이 유발되지 않은 정상 랫트에 비해 STZ에 의해 당뇨병이 유발된 실험군(Ⅴ 군) 에서는 혈중 포도당, 중성지방, 총 콜레스테롤 수치가 증가하고 인슐린 수치가 감소된 것이 확인되었다. 이에 비해 DP 를 60 mg/kg (Ⅶ 군) 또는 100 mg/kg (Ⅷ 군)로 투여한 랫트에서는 혈중 포도당 및 중성지방, 총 콜레스테롤 양이 감소하고, 인슐린 수치가 유의성 있게 증가하였다 (DP 30 mg/kg (Ⅵ 군) 투여 시에는 유의성 있는 수치 변화 보이지 않음). 이는 대조약물인 글리벤클라마이드 (60 μg/kg, Ⅸ 군) 투여군 보다 더 효능이 뛰어난 것으로, DP 가 우수한 당뇨병 치료제가 될 수 있음을 보여준다. As shown in FIG. 3, blood glucose, triglyceride and total cholesterol levels were increased and insulin levels were decreased in an experimental group (group V) in which diabetes was induced by STZ compared with normal rats not induced by diabetes. In contrast, in rats fed DP at 60 mg / kg (group Ⅶ) or 100 mg / kg (group Ⅷ), blood glucose, triglyceride and total cholesterol levels decreased and insulin levels were significantly increased (
실험예Experimental Example 4. 신장 기능에 미치는 영향 확인 (혈중 요산, 요소, 크레아틴 농도 측정) 4. Identification of effects on renal function (serum uric acid, urea, creatine concentration)
지난 연구 결과를 통해 당뇨병이 유발되었을 때 혈중 요산이 증가하는 것이 밝혀졌다. 이는 당뇨병에서 잔틴 산화 효소의 활발한 작용, 지질 과산화, 중성지방 및 콜레스테롤의 증가로 인한 대사 이상이 나타나기 때문이다. 또한 혈중의 요소 및 크레아틴의 농도 증가 역시 당뇨병을 확인할 수 있는 지표 중의 하나로 고혈당에 의해 나타나는 신장 기능 이상으로 인해 나타난다. Previous studies have shown that serum uric acid increases when diabetes is induced. This is due to the active action of xanthine oxidase in diabetes, lipid peroxidation, metabolic abnormalities due to increased triglyceride and cholesterol. Increased concentrations of urea and creatine in the blood are also among the indicators of diabetes mellitus due to hypertrophic dysfunction caused by hyperglycemia.
도 4에 나타낸 바와 같이, 당뇨병이 유발되지 않은 정상 랫트에 비해 STZ에 의해 당뇨병이 유발된 실험군(Ⅴ 군) 에서는 혈중 요산, 요소, 크레아틴 수치가 증가하여 신장 기능 이상이 생긴 것을 확인하였다. 이에 비해 DP 를 60 mg/kg (Ⅶ 군) 또는 100 mg/kg (Ⅷ 군)로 투여한 랫트에서는 혈중 혈중 요산, 요소, 크레아틴 수치가 유의성 있게 감소하였다 (DP 30 mg/kg (Ⅵ 군) 투여 시에는 유의성 있는 수치 변화 보이지 않음). 이는 대조약물인 글리벤클라마이드 (60 μg/kg, Ⅸ 군) 투여군 보다 더 효능이 뛰어난 것으로, DP 가 신장 기능 이상을 완화하여 우수한 당뇨병 치료제가 될 수 있음을 보여준다.
As shown in FIG. 4, in the experimental group (group V) in which diabetes was induced by STZ compared with normal rats in which no diabetes was induced, it was confirmed that renal function abnormality was caused by an increase in blood uric acid, urea and creatine levels. In contrast, in the rats administered DP at 60 mg / kg (group Ⅶ) or 100 mg / kg (group Ⅷ), blood serum uric acid, urea and creatine levels were significantly decreased (
실험예Experimental Example 5. 간기능에 미치는 영향 확인 (혈중 AST, 5. Identification of effects on liver function (blood AST, ALTALT 측정) Measure)
AST와 ALT는 간 이상을 확인할 수 있는 지표로, 상기 효소의 증가는 간에 손상이 있음을 나타낸다. AST and ALT are indicators of hepatic abnormality, and the increase of the enzyme indicates that there is liver damage.
도 5에 나타낸 바와 같이, 당뇨병이 유발되지 않은 정상 랫트에 비해 STZ에 의해 당뇨병이 유발된 실험군(Ⅴ 군) 에서는 혈중 AST, ALT 수치가 증가하여 간 기능 이상이 생긴 것을 확인하였다. 이에 비해 DP 를 60 mg/kg (Ⅶ 군) 또는 100 mg/kg (Ⅷ 군)로 투여한 랫트에서는 혈중 AST, ALT 수치가 유의성 있게 감소하였다 (DP 30 mg/kg (Ⅵ 군) 투여 시에는 유의성 있는 수치 변화 보이지 않음). 이는 대조약물인 글리벤클라마이드 (60 μg/kg, Ⅸ 군) 투여군 보다 더 효능이 뛰어난 것으로, DP 가 간 손상을 일으키지 않으면서도 우수한 당뇨병 치료제가 될 수 있음을 보여준다.
As shown in FIG. 5, in the experimental group (group V) in which diabetes was induced by STZ compared with normal rats in which no diabetes was induced, the levels of AST and ALT in the blood were increased and liver function abnormality was confirmed. In contrast, the AST and ALT levels in the rats treated with DP at 60 mg / kg (group Ⅶ) or 100 mg / kg (group Ⅷ) decreased significantly (
이하 본 발명의 상기 조성물을 함유하는 약학적 조성물 및 건강기능식품의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, a pharmaceutical composition containing the composition of the present invention and a preparation of a health functional food will be described, but the present invention is not intended to be limited thereto but is specifically described.
제제예Formulation example 1. One. 산제의Sanje 제조 Produce
Dendropanoxide 20 mgDendropanoxide 20 mg
유당 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예Formulation example 2. 정제의 제조 2. Preparation of tablets
Dendropanoxide 10 mgDendropanoxide 10 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
Dendropanoxide 10 mgDendropanoxide 10 mg
결정성 셀룰로오스 3 mgCrystalline cellulose 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
Dendropanoxide 10 mgDendropanoxide 10 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4 ?2H2O 26 mgNa 2 HPO 4 ? 2H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당 (2 ml) 상기의 성분 함량으로 제조한다.
(2 ml) per 1 ampoule in accordance with the usual injection preparation method.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
Dendropanoxide 20 mgDendropanoxide 20 mg
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100 ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
제제예Formulation example 6. 건강식품의 제조 6. Manufacture of health food
Dendropanoxide 100 mg
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 μg Vitamin A acetate 70 μg
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 μg Vitamin B12 0.2 μg
비타민 C 10 mgVitamin C 10 mg
비오틴 10 μg Biotin 10 μg
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 μg Folic acid 50 μg
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예Formulation example 7. 7. 건강음료의Health drink 제조 Produce
Dendropanoxide 100 mg
비타민 C 15 gVitamin C 15 g
비타민 E(분말) 100 gVitamin E (powder) 100 g
젖산철 19.75 g19.75 g of ferrous lactate
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinic acid amide 3.5 g
비타민 A 0.2 gVitamin A 0.2 g
비타민 B1 0.25 gVitamin B1 0.25 g
비타민 B2 0.3gVitamin B2 0.3g
물 정량Water quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 l 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.
The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.
Claims (7)
상기 건강기능식품은 음료인 것을 특징으로 하는 건강기능식품
The method according to claim 6,
Wherein the health functional food is a beverage,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110014116A KR101406138B1 (en) | 2011-02-17 | 2011-02-17 | Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110014116A KR101406138B1 (en) | 2011-02-17 | 2011-02-17 | Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120101743A KR20120101743A (en) | 2012-09-17 |
| KR101406138B1 true KR101406138B1 (en) | 2014-06-19 |
Family
ID=47110542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110014116A KR101406138B1 (en) | 2011-02-17 | 2011-02-17 | Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101406138B1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101443230B1 (en) * | 2012-11-20 | 2014-09-29 | 서남해안황칠협동조합 | Composition for controlling blood pressure, regulating blood sugar and improving liver function comprising extract of Dendropanax morbiferus |
| KR101283775B1 (en) * | 2013-02-04 | 2013-07-08 | 재단법인 전라남도생물산업진흥재단 | Pharmaceuticlal composition for anti-tussive activity or discharge of phlegm activity comprising extracts of dendropanax morbifera |
| KR101434994B1 (en) * | 2014-04-10 | 2014-09-15 | 농업회사법인 (주)함박재농장 | Composition for anti-obesity with the extract of Dendropanax morbifera |
| KR101467407B1 (en) * | 2014-06-05 | 2014-12-03 | 농업회사법인 (주)함박재농장 | Antidiabetic food composition with the extract of Dendropanax morbifera |
| KR101994310B1 (en) * | 2017-05-15 | 2019-07-01 | 농업회사법인 휴림황칠(주) | Composition for preventing or treating urinary stone and manufacturing method thereof |
| KR20210108748A (en) * | 2020-02-26 | 2021-09-03 | 농업회사법인 휴림황칠(주) | A composition containing an extract of dendropanax morbifera for hypernricemia |
| KR20220001801A (en) * | 2020-06-30 | 2022-01-06 | 주식회사 고암바이오알앤디수 | Composition for preventing or treating nephrotoxicity and renal fibrosis comprising dendropanax morbifera extract or compound isolated therefrom |
| KR102447045B1 (en) * | 2020-10-21 | 2022-09-22 | 성균관대학교산학협력단 | Composition containing an extract of dendropanax morbifera |
-
2011
- 2011-02-17 KR KR1020110014116A patent/KR101406138B1/en active IP Right Grant
Non-Patent Citations (4)
| Title |
|---|
| 2010 International Symposium and Annual Meeting, 한국식품영양과학회, S15-4 * |
| 2010 International Symposium and Annual Meeting, 한국식품영양과학회, S15-4* |
| Journal of Ethnopharmacology, 2004, 90, pp. 403-408 * |
| Journal of Ethnopharmacology, 2004, 90, pp. 403-408* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120101743A (en) | 2012-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101406138B1 (en) | Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille | |
| KR101383146B1 (en) | Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease | |
| KR102132655B1 (en) | Composition containing chrysanthemum zawadskii extract | |
| KR101443230B1 (en) | Composition for controlling blood pressure, regulating blood sugar and improving liver function comprising extract of Dendropanax morbiferus | |
| KR100829057B1 (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and propolis and process for preparing the same | |
| KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
| KR101731152B1 (en) | Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof | |
| KR101536974B1 (en) | Composition for preventing and improving diabetes comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
| KR101723022B1 (en) | Composition for preventing or alleviating hangover comprising extracts of catalpa ovata g. don | |
| KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
| KR101449670B1 (en) | Composition for preventing or treating diabetes or complications of diabetes mellitus comprising Rhododendron mucronulatum for. albiflorum extract | |
| KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
| KR101999383B1 (en) | Pharmaceutical Composition for Improving, Protecting or Treating Alcoholic Liver Disease comprising Capsosiphon fulvescens Extract as Active Ingredient | |
| KR101808808B1 (en) | Compositions for preventing and treating diabetes or diabetic complications comprising extracts of Acer tegmentosum Maximowoca and Magnolia officinalis Rehd. et Wils. | |
| KR101157096B1 (en) | Composition for relieving hangover containing Bulnesia sarmienti extracts | |
| KR100940133B1 (en) | Anti- diabetic composition containing crude extracts of Citrus aurantium and health assistant foods with valid component thereof | |
| KR20210078693A (en) | A composition for improving liver function comprising Artemisia Annua extract | |
| KR100535322B1 (en) | Pharmaceutical composition comprising the extract of Allium tuberosum Rottler for treating or preventing diabetes mellitus | |
| KR20150015611A (en) | Composition comprising Saussurea grandifolia extract or compound isolated from the same for preventing or treating of diabetic complication | |
| KR102567159B1 (en) | Extract of Ligularia fischeriof as α-glucosidase inhibitor | |
| KR101226881B1 (en) | A composition comprising the extract of Proso millet as an active ingredient for preventing and treating inflammatory disease | |
| US9132160B2 (en) | Composition for preventing and/or alleviating hangover comprising extracts of sophora flavescens | |
| KR20100083598A (en) | Composition for preventing and treating type ii diabetes comprising the extract of ginseng flower | |
| KR20230099707A (en) | Composition for preventing or relieving hangovers containing extracts from natural materials | |
| KR20230158317A (en) | Composition for the prevention or treatment of degenerative neurological diseases, comprising the extract of Sasa quelpaertensis as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170601 Year of fee payment: 4 |